246 related articles for article (PubMed ID: 36775130)
1. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
[TBL] [Abstract][Full Text] [Related]
3. Genetic Surveillance of SARS-CoV-2 M
Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.
Duan Y; Zhou H; Liu X; Iketani S; Lin M; Zhang X; Bian Q; Wang H; Sun H; Hong SJ; Culbertson B; Mohri H; Luck MI; Zhu Y; Liu X; Lu Y; Yang X; Yang K; Sabo Y; Chavez A; Goff SP; Rao Z; Ho DD; Yang H
Nature; 2023 Oct; 622(7982):376-382. PubMed ID: 37696289
[TBL] [Abstract][Full Text] [Related]
5. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
[TBL] [Abstract][Full Text] [Related]
6. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease.
Flynn JM; Huang QYJ; Zvornicanin SN; Schneider-Nachum G; Shaqra AM; Yilmaz NK; Moquin SA; Dovala D; Schiffer CA; Bolon DNA
ACS Infect Dis; 2023 Jul; 9(7):1372-1386. PubMed ID: 37390404
[TBL] [Abstract][Full Text] [Related]
7. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
[TBL] [Abstract][Full Text] [Related]
8. Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
Bouzidi HS; Driouich JS; Klitting R; Bernadin O; Piorkowski G; Amaral R; Fraisse L; Mowbray CE; Scandale I; Escudié F; Chatelain E; de Lamballerie X; Nougairède A; Touret F
Antiviral Res; 2024 Feb; 222():105814. PubMed ID: 38272321
[TBL] [Abstract][Full Text] [Related]
9. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
[TBL] [Abstract][Full Text] [Related]
10. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
Tan B; Sacco M; Tan H; Li K; Joyce R; Zhang X; Chen Y; Wang J
Eur J Med Chem; 2023 Nov; 259():115667. PubMed ID: 37482021
[TBL] [Abstract][Full Text] [Related]
11. Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors.
Ghosh AK; Yadav M; Iddum S; Ghazi S; Lendy EK; Jayashankar U; Beechboard SN; Takamatsu Y; Hattori SI; Aamano M; Higashi-Kuwata N; Mitsuya H; Mesecar AD
Eur J Med Chem; 2024 Mar; 267():116132. PubMed ID: 38335815
[TBL] [Abstract][Full Text] [Related]
12. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
[TBL] [Abstract][Full Text] [Related]
13. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
Ullrich S; Ekanayake KB; Otting G; Nitsche C
Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 3CL
Heilmann E; Costacurta F; Moghadasi SA; Ye C; Pavan M; Bassani D; Volland A; Ascher C; Weiss AKH; Bante D; Harris RS; Moro S; Rupp B; Martinez-Sobrido L; von Laer D
Sci Transl Med; 2023 Jan; 15(678):eabq7360. PubMed ID: 36194133
[TBL] [Abstract][Full Text] [Related]
15. In silico investigation of Komaroviquinone as a potential inhibitor of SARS-CoV-2 main protease (Mpro): Molecular docking, molecular dynamics, and QM/MM approaches.
Santos SJM; Valentini A
J Mol Graph Model; 2024 Jan; 126():108662. PubMed ID: 37950976
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
Tan B; Joyce R; Tan H; Hu Y; Wang J
Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants.
Lin M; Zeng X; Duan Y; Yang Z; Ma Y; Yang H; Yang X; Liu X
Commun Biol; 2023 Jul; 6(1):694. PubMed ID: 37407698
[TBL] [Abstract][Full Text] [Related]
19. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.
Padhi AK; Tripathi T
Biochem Biophys Res Commun; 2022 Nov; 629():54-60. PubMed ID: 36113178
[TBL] [Abstract][Full Text] [Related]
20. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
